Multiplexed functional assessments of MYH7 variants in human cardiomyocytes at scale

Background Single, autosomal-dominant missense mutations in MYH7, which encodes a sarcomeric protein (MHC-β) in cardiac and skeletal myocytes, are a leading cause of hypertrophic cardiomyopathy and are clinically-actionable. However, ∼75% of MYH7 variants are of unknown significance (VUS), causing diagnostic challenges for clinicians and emotional distress for patients. Deep mutational scans (DMS) can determine variant effect at scale, but have only been utilized in easily-editable cell lines. While human induced pluripotent stem cells (hiPSCs) can be differentiated to numerous cell types that enable the interrogation of variant effect in a disease-relevant context, DMS have not been executed using diploid hiPSC derivates. However, CRaTER enrichment has recently enabled the pooled generation of a saturated five position MYH7 variant hiPSC library suitable for DMS for the first time. Results As a proof-of-concept, we differentiated this MYH7 variant hiPSC library to cardiomyocytes (hiPSC-CMs) for multiplexed assessment of MHC-β variant abundance by massively parallel sequencing (VAMP-seq) and hiPSC-CM survival. We confirm MHC-β protein loss occurs in a failing human heart with a pathogenic MYH7 mutation. We find the multiplexed assessment of MHC-β abundance and hiPSC-CM survival both accurately segregate all pathogenic variants from synonymous controls. Overall, functional scores of 68 amino acid substitutions across these independent assays are ∼50% consistent. Conclusions This study leverages hiPSC differentiation into disease-relevant cardiomyocytes to enable multiplexed assessments of MYH7 missense variants at scale for the first time. This proof-of-concept demonstrates the ability to DMS previously restricted, clinically-actionable genes to reduce the burden of VUS on patients and clinicians.

[1]  David T. Miller,et al.  ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). , 2023, Genetics in medicine : official journal of the American College of Medical Genetics.

[2]  N. Sniadecki,et al.  Cardiomyocyte Apoptosis Is Associated with Contractile Dysfunction in Stem Cell Model of MYH7 E848G Hypertrophic Cardiomyopathy , 2023, International journal of molecular sciences.

[3]  L. Starita,et al.  CRaTER enrichment for on-target gene-editing enables generation of variant libraries in hiPSCs , 2023, bioRxiv.

[4]  M. Claussnitzer,et al.  Scalable Functional Assays for the Interpretation of Human Genetic Variation. , 2022, Annual review of genetics.

[5]  Beau R. Webber,et al.  Myosin Heavy Chain Converter Domain Mutations Drive Early-Stage Changes in Extracellular Matrix Dynamics in Hypertrophic Cardiomyopathy , 2022, bioRxiv.

[6]  C. Marboe,et al.  Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy , 2022, Circulation.

[7]  Alan F. Rubin,et al.  Closing the gap: Systematic integration of multiplexed functional data resolves variants of uncertain significance in BRCA1, TP53, and PTEN. , 2021, American journal of human genetics.

[8]  Aidan N. Gomez,et al.  Disease variant prediction with deep generative models of evolutionary data , 2021, Nature.

[9]  W. Chung,et al.  ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG) , 2021, Genetics in Medicine.

[10]  Matthew W. Martinez,et al.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.

[11]  J. Spudich,et al.  Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state , 2020, Proceedings of the National Academy of Sciences.

[12]  Yu-Sheng Chen,et al.  Development of a Cardiac Sarcomere Functional Genomics Platform to Enable Scalable Interrogation of Human TNNT2 Variants , 2020, Circulation.

[13]  E. Ashley,et al.  Silencing of MYH7 ameliorates disease phenotypes in human iPSC-Cardiomyocytes. , 2020, Physiological genomics.

[14]  C. Denning,et al.  Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics , 2020, Journal of molecular and cellular cardiology.

[15]  J. F. Staples,et al.  Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy , 2020, Circulation.

[16]  C. Mummery,et al.  Inherited cardiac diseases, pluripotent stem cells, and genome editing combined—the past, present, and future , 2019, Stem cells.

[17]  K. Musunuru,et al.  Functional Annotation of TNNT2 Variants of Uncertain Significance With Genome-Edited Cardiomyocytes. , 2018, Circulation.

[18]  Deok‐Ho Kim,et al.  Novel Adult-Onset Systolic Cardiomyopathy Due to MYH7 E848G Mutation in Patient-Derived Induced Pluripotent Stem Cells , 2018, JACC. Basic to translational science.

[19]  Z. Bar-Joseph,et al.  Single-Cell Transcriptomic Analysis of Cardiac Differentiation from Human PSCs Reveals HOPX-Dependent Cardiomyocyte Maturation. , 2018, Cell stem cell.

[20]  Chris Denning,et al.  CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy , 2018, European heart journal.

[21]  Vanessa E. Gray,et al.  Multiplex Assessment of Protein Variant Abundance by Massively Parallel Sequencing , 2018, Nature Genetics.

[22]  Birgit Funke,et al.  Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel , 2018, Genetics in Medicine.

[23]  B. Hadland,et al.  Generating high-purity cardiac and endothelial derivatives from patterned mesoderm using human pluripotent stem cells , 2016, Nature Protocols.

[24]  D. MacArthur,et al.  Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples , 2016, Genetics in Medicine.

[25]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[26]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[27]  Matthew S. Lebo,et al.  Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity , 2015, Genetics in Medicine.

[28]  Bin Zhang,et al.  PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..

[29]  M. Peckham,et al.  Structural Implications of β‐Cardiac Myosin Heavy Chain Mutations in Human Disease , 2014, Anatomical record.

[30]  Jiajie Zhang,et al.  PEAR: a fast and accurate Illumina Paired-End reAd mergeR , 2013, Bioinform..

[31]  Gordon Keller,et al.  Differentiation of Embryonic Stem Cells to Clinically Relevant Populations: Lessons from Embryonic Development , 2008, Cell.

[32]  J. Moult,et al.  Loss of protein structure stability as a major causative factor in monogenic disease. , 2005, Journal of molecular biology.

[33]  Claudine Attias-Donfut,et al.  Analyses , 1994, Gérontologie et société.

[34]  N. Dokholyan,et al.  Protein Destabilization as a Common Factor in Diverse Inherited Disorders , 2015, Journal of Molecular Evolution.

[35]  I. Schlichting,et al.  Crystal structures of human cardiac beta-myosin II S2-Delta provide insight into the functional role of the S2 subfragment. , 2006, Proceedings of the National Academy of Sciences of the United States of America.